Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
McKesson
UBS
Novartis
Federal Trade Commission
Daiichi Sankyo
Deloitte
Johnson and Johnson
Cantor Fitzgerald
Accenture

Generated: October 23, 2017

DrugPatentWatch Database Preview

Baxter Hlthcare Company Profile

« Back to Dashboard

What is the competitive landscape for BAXTER HLTHCARE, and what generic alternatives to BAXTER HLTHCARE drugs are available?

BAXTER HLTHCARE has one hundred and ninety-two approved drugs.

There are six US patents protecting BAXTER HLTHCARE drugs. There are two tentative approvals on BAXTER HLTHCARE drugs.

There are one hundred and fifteen patent family members on BAXTER HLTHCARE drugs in thirty-five countries and one hundred and forty-three supplementary protection certificates in twelve countries.

Summary for Applicant: Baxter Hlthcare

International Patents:115
US Patents:6
Tradenames:302
Ingredients:109
NDAs:192
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Baxter Hlthcare
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ
dextrose; potassium chloride; sodium chloride
INJECTABLE;INJECTION018037-005Apr 13, 1982APRXNoNo► Subscribe► Subscribe► Subscribe
Baxter Hlthcare
TRAVASOL 8.5% W/ ELECTROLYTES
amino acids; magnesium chloride; potassium phosphate, dibasic; sodium acetate; sodium chloride
INJECTABLE;INJECTION017493-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Baxter Hlthcare
TRAVASOL 10% W/O ELECTROLYTES
amino acids
INJECTABLE;INJECTION017493-006Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Baxter Hlthcare
DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
calcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactate
SOLUTION;INTRAPERITONEAL017512-007Jul 9, 1984ATRXNoNo► Subscribe► Subscribe► Subscribe
Baxter Hlthcare
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
dextrose; sodium chloride
INJECTABLE;INJECTION016696-001Approved Prior to Jan 1, 1982APRXNoNo► Subscribe► Subscribe► Subscribe
Baxter Hlthcare Corp
SPARINE
promazine hydrochloride
INJECTABLE;INJECTION010349-006Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Baxter Hlthcare
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER
dobutamine hydrochloride
INJECTABLE;INJECTION020255-005Oct 19, 1993APRXYesYes► Subscribe► Subscribe► Subscribe
Baxter Hlthcare
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
dextrose; potassium chloride; sodium chloride
INJECTABLE;INJECTION018008-008Apr 28, 1982APRXNoNo► Subscribe► Subscribe► Subscribe
Baxter Hlthcare
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER
amino acids; dextrose
INJECTABLE;INJECTION020734-016Sep 29, 1997RXNoNo► Subscribe► Subscribe► Subscribe
Baxter Hlthcare
CYTOXAN
cyclophosphamide
INJECTABLE;INJECTION012142-002Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Baxter Hlthcare

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Baxter Hlthcare
MESNEX
mesna
TABLET;ORAL020855-001Mar 21, 2002► Subscribe► Subscribe
Baxter Hlthcare
MESNEX
mesna
INJECTABLE;INTRAVENOUS019884-001Dec 30, 1988► Subscribe► Subscribe
Baxter Hlthcare
IFEX/MESNEX KIT
ifosfamide; mesna
INJECTABLE;INJECTION019763-004Oct 10, 1992► Subscribe► Subscribe
Baxter Hlthcare Corp
CLINOLIPID 20%
olive oil; soybean oil
INJECTABLE;INJECTION204508-001Oct 3, 2013► Subscribe► Subscribe
Baxter Hlthcare
CYTOXAN (LYOPHILIZED)
cyclophosphamide
INJECTABLE;INJECTION012142-008Jan 4, 1984► Subscribe► Subscribe
Baxter Hlthcare
IFEX/MESNEX KIT
ifosfamide; mesna
INJECTABLE;INJECTION019763-003Oct 10, 1992► Subscribe► Subscribe
Baxter Hlthcare
SUPRANE
desflurane
LIQUID;INHALATION020118-001Sep 18, 1992► Subscribe► Subscribe
Baxter Hlthcare Corp
PRALIDOXIME CHLORIDE
pralidoxime chloride
INJECTABLE;INJECTION018799-001Dec 13, 1982► Subscribe► Subscribe
Baxter Hlthcare
IFEX/MESNEX KIT
ifosfamide; mesna
INJECTABLE;INJECTION019763-003Oct 10, 1992► Subscribe► Subscribe
Baxter Hlthcare
ETHRANE
enflurane
LIQUID;INHALATION017087-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for BAXTER HLTHCARE drugs

Drugname Dosage Strength Tradename Submissiondate
esmolol hydrochloride
Injection10 mg/mL, 250 mL infusion bags and 20 mg/mL, 100 mL infusion bags
BREVIBLOC
1/31/2014
desflurane
Inhalation99.90%
SUPRANE
9/11/2008

Non-Orange Book Patents for Baxter Hlthcare

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
4,886,789 Peritoneal dialysis and compositions for use therein► Subscribe
9,200,088Sulfoalkyl ether cyclodextrin compositions► Subscribe
8,410,077Sulfoalkyl ether cyclodextrin compositions► Subscribe
9,750,822Sulfoalkyl ether cyclodextrin compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Baxter Hlthcare Drugs

Country Document Number Estimated Expiration
Austria535239► Subscribe
Norway850603► Subscribe
Spain2567716► Subscribe
United Kingdom8404299► Subscribe
Germany3577402► Subscribe
Japan4764004► Subscribe
Australia3863085► Subscribe
World Intellectual Property Organization (WIPO)2009134347► Subscribe
China1775207► Subscribe
Germany60215129► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Baxter Hlthcare Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
128Luxembourg► SubscribePRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-INYL-3-METHYL-1-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3, 7-DIHYDROPURIN-2, 6-DION, LES ENANTIOMERES ET LEURS SELS, EN PARTICULIER LA LINAGLIPTINE COMBINEE AVEC DU CHLORHYDRATE DE METFORMINE. LINAGLIPTINE
90025-6Sweden► SubscribePRODUCT NAME: MEMANTIN, 1-AMINO-3,5-DIMETYLADAMANTAN; REGISTRATION NO/DATE: EU/1/02/219/001 20020515
90020-1Sweden► SubscribePRODUCT NAME: SACUBITRIL AND VALSARTAN, AS SACUBITRIL VALSARTAN SODIUM SALT COMPLEX, I.E. TRISODIUM 3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3- ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3-METHYL-2- (PENTANOYL2-(TETRAZOL-5-YLATE)BIPHENYL-4- YLMETHYLAMINO)BUTYRATE HEMIPENTAHYDRATE; REG. NO/DATE: EU/1/15/1058 20151123
00517Netherlands► SubscribePRODUCT NAME: ACETYLSALICYLZUUR EN ESOMEPRAZOLMAGNESIUMTRIHYDRAAT; NAT. REGISTRATION NO/DATE: RVG 107516 20110912; FIRST REGISTRATION: 540235954023675402375 2011120812
C/GB98/042United Kingdom► SubscribePRODUCT NAME: 2-ETHOXY-4-(1-(2-PIPERIDINO-PHENYL)-3-METHYL-1-BUTYL)-AMINOCARBONYLMETHYL)-BENZOIC ACID, OPTIONALLY IN THE FORM OF A PHYSIOLOGICALLY ACCEPTABLE SALT AND/OR OPTIONALLY IN THE FORM OF AN ENANTIOMER, IN PARTICULAR (S)(+)-2-ETHOXY-4-(1-(2-PIPERIDINO-PHENYL)-3; REGISTERED: UK EU/1/98/076/001 19980817; UK EU/1/98/076/002 19980817; UK EU/1/98/076/003 19980817; UK EU/1/98/076/004 19980817; UK EU/1/98/076/005 19980817; UK EU/1/98/076/006 19980817; UK EU/1/98/076/019 19980817; UK EU/1/98/076/020 19980817; UK EU/1/98/076/021 19980817; UK EU/1/98/076/013 19980817; UK EU/1/98/076/014 19980817; UK EU/1/98/076/015 19980817; UK EU/1/98/076/016 19980817; UK EU/1/98/076/017 19980817; UK EU/1/98/
C/GB08/036United Kingdom► SubscribePRODUCT NAME: MICAFUNGIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN PARTICULAR MICAFUNGIN SODIUM; REGISTERED: UK EU/1/08/448/001 20080425; UK EU/1/08/448/002 20080425
0483Netherlands► SubscribePRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMTRIHYDRAAT; NATIONAL REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: GB PL 17091/0263 - 0001 20101105
C/GB03/014United Kingdom► SubscribePRODUCT NAME: 3 METHYLAMINO-6-CARBOXAMIDO-1, 2, 3, 4-TETRAHYDROCARBAZOLE ("FROVATRIPTAN") INCLUDING A SALT, SOLVATE OR HYDRATE THEREOF; REGISTERED: FR NL 24548 20001212; UK PL 16239/0017 20021007; UK PL 16239/0018 20021007
00482Netherlands► SubscribePRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMZOUT; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17091/0263 - 0001 20101105
2012Austria► SubscribePRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-INYL-3-METHYL-1-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3,7-DIHYDROPURIN-2,6-DION UND DESSEN SALZE, INSBES. LINAGLIPTIN; REGISTRATION NO/DATE: EU/1/11/707/001-011 (MITTEILUNG) 20110830
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Queensland Health
Citi
Federal Trade Commission
Healthtrust
Express Scripts
Merck
UBS
Deloitte
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot